| Old Articles: <Older 6851-6860 Newer> |
|---|
 |
The Motley Fool
November 1, 2010
Brian Orelli |
Stock Doubles! No Crying Here AVANIR Pharmaceuticals' investors didn't have any uncontrolled crying on Friday when the Food and Drug Administration approved Nuedexta, the company's treatment for pseudobulbar affect.   |
The Motley Fool
November 1, 2010
Sean Williams |
Somaxon Pharmaceuticals: Bargain or Value Trap? A strong balance sheet and Procter & Gamble could make this a value play. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
October 30, 2010
Anand Chokkavelu |
7 Pharma Stocks Near 52-Week Highs Here are the top seven companies in the pharmaceutical space (by market cap) that are within spitting distance of their 52-week highs: J&J... Novartis... Merck... GlaxoSmithKline... Abbott... AstraZeneca... Novo Nordisk... |
The Motley Fool
October 28, 2010
Brian Orelli |
This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37. |
The Motley Fool
October 28, 2010 |
Our Top Stock Idea Our investing community's latest prime pick -- Medco Health Solutions. |
The Motley Fool
October 28, 2010
Brian Stoffel |
Would Peter Lynch Like This Small Cap? We'll put Continuecare through the test. |
The Motley Fool
October 28, 2010
Anand Chokkavelu |
7 Health-Care Stocks Near 52-Week Highs Searching the market's peaks for possibilities. |
CIO
October 27, 2010
Cindy Waxer |
How Mayo Clinic Doctors Use Smartphones to Diagnose Patients Neurologists diagnose patients remotely using images delivered to smartphones. |
The Motley Fool
October 27, 2010
Brian Orelli |
Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan. |
| <Older 6851-6860 Newer> Return to current articles. |
